|
Synonyms: ESK-001 | ESK001
Compound class:
Synthetic organic
Comment: The chemical structure for envudeucitinib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a Janus kinase inhibitor with anti-inflammatory potential. It was later disclosed as an orally bioavailable allosteric TYK2 inhibitor, with company code ESK-001 [1,3]. Envudeucitinib targets the allosteric pseudokinase structural domain (JH2) of TYK2.
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Armstrong AW, Krueger JG, Strober BE, Stein Gold LF, Desai SR, Muscianisi E, Klyachkin Y, Ucpinar S, Tilley MK, Blauvelt A. (2026)
Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review. Dermatol Ther (Heidelb), 16 (6): 2661-2673. [PMID:41934538] |
|
2. Blauvelt A, Arenberger P, Sauder MB, Couvillion M, Rubio RG, Vlahakis NE, Ucpinar S, Ma G, Hitraya E, Tilley MK et al.. (2026)
Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study. J Am Acad Dermatol, 94 (1): 57-65. [PMID:40659116] |
|
3. Deng L, Wan L, Liao T, Wang L, Wang J, Wu X, Shi J. (2023)
Recent progress on tyrosine kinase 2 JH2 inhibitors. Int Immunopharmacol, 121: 110434. [PMID:37315371] |
|
4. Loo WJ, Turchin I, Prajapati VH, Gooderham MJ, Grewal P, Hong CH, Sauder M, Vender RB, Maari C, Papp KA. (2023)
Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway. J Cutan Med Surg, 27 (1_suppl): 3S-24S. [PMID:36519621] |